| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Staidson (Beijing) BioPharmaceuticals Co. Ltd (SHE: 300204)
300204 Technical Analysis
4
| As on 24th Apr 2025 300204 SHARE Price closed @ 11.94 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.66 & Buy for SHORT-TERM with Stoploss of 10.62 we also expect STOCK to react on Following IMPORTANT LEVELS. |
300204SHARE Price
| Open | 10.76 | Change | Price | % |
| High | 12.40 | 1 Day | 1.13 | 10.45 |
| Low | 10.68 | 1 Week | 4.16 | 53.47 |
| Close | 11.94 | 1 Month | 4.45 | 59.41 |
| Volume | 62466322 | 1 Year | 2.87 | 31.64 |
| 52 Week High 12.74 | 52 Week Low 5.45 | ||||
SHE China Most Active Stocks
| 000560 | 3.65 | 5.80% |
| 002570 | 7.27 | 6.60% |
| 000617 | 7.42 | -5.12% |
| 002537 | 8.95 | 9.95% |
| 002131 | 3.40 | -3.95% |
| 002094 | 9.14 | 2.24% |
| 002640 | 3.98 | -7.01% |
| 002251 | 6.69 | 10.03% |
| 300180 | 8.36 | -2.11% |
| 000965 | 5.21 | 9.92% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
| 300204 Daily Charts |
300204 Intraday Charts |
Whats New @ Bazaartrend |
300204 Free Analysis |
|
|
300204 Important Levels Intraday
| RESISTANCE | 15.25 |
| RESISTANCE | 14.19 |
| RESISTANCE | 13.53 |
| RESISTANCE | 12.88 |
| SUPPORT | 11.00 |
| SUPPORT | 10.35 |
| SUPPORT | 9.69 |
| SUPPORT | 8.63 |
300204 Forecast April 2025
| 4th UP Forecast | 17.91 |
| 3rd UP Forecast | 16 |
| 2nd UP Forecast | 14.81 |
| 1st UP Forecast | 13.63 |
| 1st DOWN Forecast | 10.25 |
| 2nd DOWN Forecast | 9.07 |
| 3rd DOWN Forecast | 7.88 |
| 4th DOWN Forecast | 5.97 |
300204 Weekly Forecast
| 4th UP Forecast | 15.10 |
| 3rd UP Forecast | 14.09 |
| 2nd UP Forecast | 13.46 |
| 1st UP Forecast | 12.83 |
| 1st DOWN Forecast | 11.05 |
| 2nd DOWN Forecast | 10.42 |
| 3rd DOWN Forecast | 9.79 |
| 4th DOWN Forecast | 8.78 |
300204 Forecast2025
| 4th UP Forecast | 27.2 |
| 3rd UP Forecast | 22.31 |
| 2nd UP Forecast | 19.28 |
| 1st UP Forecast | 16.26 |
| 1st DOWN Forecast | 7.62 |
| 2nd DOWN Forecast | 4.6 |
| 3rd DOWN Forecast | 1.57 |
| 4th DOWN Forecast | -3.32 |
Staidson (Beijing) BioPharmaceuticals Co. Ltd ( SHE China Symbol : 300204 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
300204 Business Profile
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China. Address: No. 36, Jinghai Er Road, Beijing, China, 100176
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service